An Open-Label Study to Assess the Effect of CYP2D6 Inhibitor Paroxetine on the Single-Dose Pharmacokinetics of JNJ-31001074 in Healthy Subjects.

Trial Profile

An Open-Label Study to Assess the Effect of CYP2D6 Inhibitor Paroxetine on the Single-Dose Pharmacokinetics of JNJ-31001074 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2014

At a glance

  • Drugs Bavisant (Primary) ; Paroxetine
  • Indications Attention-deficit hyperactivity disorder; Depression; Generalised anxiety disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 19 Mar 2012 Actual initiation date changed from Sep 2010 to Aug 2010 as reported by ClinicalTrials.gov.
    • 04 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top